<DOC>
	<DOCNO>NCT00278564</DOCNO>
	<brief_summary>Myositis disease , believe due immune cell , cell normally protect body , attack muscle organ system within body . As result , affect muscle organ fail work properly cause weakness , difficulty swallowing , skin rash , respiratory problem , heart problem , joint stiffness , soft tissue calcification vasculitis ( blood circulation problem ) . The likelihood progression disease high . This study design examine whether treat patient high dose cyclophosphamide ( drug reduces function immune system ) ATG ( protein kill immune cell think cause disease ) , follow return previously collect blood stem cell stop progression myositis .</brief_summary>
	<brief_title>Stem Cell Transplantation Idiopathic Inflammatory Myopathy Diseases</brief_title>
	<detailed_description>Conditioning Regimen ( In order assure sterility testing , minimum 14 day require stem cell collection start condition regimen ) . The condition regimen outline : Cyclophosphamide 50 mg/kg/day give IV 1 hour 250 cc normal saline day -5 , -4 , -3 , -2 . If actual weight &lt; ideal weight , cyclophosphamide give base actual weight . If actual weight &gt; ideal weight , cyclophosphamide give adjusted ideal weight . Adjusted ideal weight = ideal weight + 40 % ( actual weight minus ideal weight ) . Mesna 50mg/kg/day give IV 24 hour 250 cc normal saline D5W start 10AM dose . Weight base calculate cyclophosphamide . 1ATG ( rabbit ) 0.5 mg/kg day -6 1mg/kg day -5 , -4 , -3 , -2 -1 ( total 5.5mg/kg , dose adjustment ) give IV 10 hour 250 cc normal saline begin least 1 hour infusion cyclophosphamide . Premedicate acetaminophen 650 mg po diphenhydramine 25 mg po/IV 30 minute infusion . Methylprednisolone A suggest dose 250mg IV administer 30 minute ATG infusion . Hydration A suggested rate 125 cc/hr NS give start 6 hour first cyclophosphamide dose continue 24 hour last cyclophosphamide dose . The rate hydration aggressively adjust . BID weight obtain . Amount fluid modify base patient 's fluid status . Minimum target urine output 2 liters/m2/day G-CSF 5 mcg/kg/day give subcutaneously continue absolute neutrophil count reach least 500/µl . Rituxan 500 mg give IV day first dose ATG day stem cell infusion .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<criteria>1 . Age ≥ 16 year ≤ 65 year time pretransplant evaluation . 2 . An establish diagnosis polymyositis , dermatomyositis , juvenile polymyositis/dermatomyositis , myositis associate collagen disease . Diagnosis require electrophysiological study histopathologic feature . MRI evidence muscle inflammation histological evidence active myositis mandatory entry . If patient dermatomyositis/polymyositis associate malignancy , patient free malignancy 5 year consider cure . 3 . Patients fail conventional treatment least 3 month duration include highdose corticosteroid ( equivalent dosage prednisone &gt; 1.0 mg/kg/day start ) , must also fail two following : cyclophosphamide , azathioprine , 6MP , methotrexate , tacrolimus , cyclosporin A , mycophenolate mofetil , TNF inhibitor ( e.g . etanercept ) , IVIG immunosuppressive drug immune modulate drug . 4 . Failure define ( one follow ) ( cause unrelated condition ) : Persistent muscle weakness ( grade 4/5 bad MRC ) elevation muscle derive enzyme ( CPK , aldolase ) Worsening pulmonary function especially % VC DLCo &gt; 15 % 12 month indicate active alveolitis . Abnormal EKG echocardiographic evidence cardiomyopathy . Presence progressive joint contracture , progressive calcinosis , vasculitis , skin ulcer juvenile dermatomyositis/polymyositis . 1 . Poor performance ( PS ) status ( ECOG &gt; 2 ) time entry , unless decline PS due disease . 2 . Significant end organ damage ( caused IIM ) : LVEF &lt; 40 % deterioration LVEF exercise test MUGA echocardiogram . Untreated lifethreatening arrhythmia . Active ischemic heart disease heart failure . DLCo &lt; 40 % FEV1/FEV &lt; 50 % . Serum creatinine &gt; 2.5 creatinine clearance &lt; 30ml/min . Liver cirrhosis , transaminases &gt; 3x normal limit bilirubin &gt; 2.0 unless due Gilbert disease . 3 . HIV positive . 4 . Uncontrolled diabetes mellitus , illness opinion investigator would jeopardize ability patient tolerate aggressive treatment . 5 . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . 6 . Positive pregnancy test , inability unable pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy . 7 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . 8 . Inability give inform consent . 9 . Major hematological abnormality platelet count less 100,000/ul , ANC le 1000/ul .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>